Repertoire Immune Medicines
Address: One Kendall Square Building 1400W,, 5th Floor, Cambridge, MA 02139About Us
Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease. The company’s proprietary DECODE™ platform provides a comprehensive understanding of the interactions between T cell receptors and their antigens in disease. DECODE uniquely elucidates the entire immune synapse, including the T-cell receptor-epitope pairs that defines it, the HLA context, and the T cell phenotype. This capability enables the creation of new and potentially transformative classes of immune-based medicines. Repertoire believes the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. The company is utilizing the discoveries from DECODE to design and develop novel immune therapies for multiple therapeutic areas, such as autoimmune diseases, infectious diseases, and cancer. The team operates from sites in Cambridge, Massachusetts and Zurich. To learn more about Repertoire, please visit www.repertoire.com.
Sectors
- Proprietary Research & Manufacture
- Collaborations & Partnerships- R&D
Categories
- Biotechnology
- Biologics
- T-Cells
- Antigens
- Immunotherapy
- immuno-oncology
- Autoimmune Products
- Platform Technology-Drug Discovery
- Clinical Development-Pipeline
News
Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly for Autoimmune Diseases
CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is common with currently available therapies.
Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech
CAMBRIDGE, Mass. – April 23, 2025 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will deploy its DECODE™ platform, which uniquely maps the immune synapse, to discover novel therapeutic targets.
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration
Collaboration combines Repertoire’s industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb’s world-leading expertise in developing and commercializing innovative immune medicines
Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com